Sun Pharmaceutical Industries Beheer
Beheer criteriumcontroles 1/4
De CEO Sun Pharmaceutical Industries is Kirti Ganorkar, benoemd in Sep2025, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0% van de aandelen van het bedrijf, ter waarde ₹ 18.03M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.1 jaar en 3 jaar.
Belangrijke informatie
Kirti Ganorkar
Algemeen directeur
n/a
Totale compensatie
| Percentage CEO-salaris | n/a |
| Dienstverband CEO | less than a year |
| Eigendom CEO | 0.0004% |
| Management gemiddelde ambtstermijn | 1.1yrs |
| Gemiddelde ambtstermijn bestuur | 3yrs |
Recente managementupdates
Recent updates
Narratiefupdate • Jun 02
SUNPHARMA: Obesity And Diabetes Franchise Will Support Bullish Long Term Outlook
Analysts have nudged their price target for Sun Pharmaceutical Industries higher from ₹1,992.47 to ₹2,039.91, citing slightly adjusted expectations for revenue growth, profit margins and future P/E assumptions. What's in the News Sun Pharma plans to share updated results from the locally advanced cutaneous squamous cell carcinoma expansion cohort of the pivotal CK-301-101 trial of UNLOXCYT (cosibelimab ipdl) at the 2026 ASCO Annual Meeting in Chicago, highlighting efficacy, durability of responses and a detailed safety profile.Analyseartikel • May 24
Do Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Narratiefupdate • May 11
SUNPHARMA: Obesity Therapies And Organon Deal Prospects Will Shape Balanced Outlook
Analysts have nudged their price target for Sun Pharmaceutical Industries higher from about ₹1,959 to roughly ₹1,992, reflecting updated assumptions around revenue growth, profit margins and future P/E multiples. What's in the News Sun Pharmaceutical Industries is reported to be close to finalising a deal to acquire assets of Organon & Co. in a transaction valued at over US$12b, funded through a mix of debt from global banks and internal cash reserves, with an announcement expected soon (CNBC-TV18, M&A rumors and discussions).Narratiefupdate • Apr 26
SUNPHARMA: Obesity And Diabetes Launches Will Drive A Constructive Outlook
Analysts have nudged their price target on Sun Pharmaceutical Industries slightly higher to ₹1,958.92 from ₹1,956.28, citing updated assumptions around revenue growth, profit margins and future P/E that leave their overall valuation framework largely intact. What's in the News The US FDA accepted a supplemental Biologics License Application for ILUMYA for adults with active psoriatic arthritis, with a regulatory action date expected by October 29, 2026.Narratiefupdate • Apr 11
SUNPHARMA: Obesity And Diabetes Launches Will Support A Constructive Outlook
Analysts have trimmed their price target for Sun Pharmaceutical Industries by about ₹5 to reflect slightly adjusted assumptions on fair value, revenue, profit margins, and future P/E expectations. What's in the News US FDA accepted a supplemental Biologics License Application for ILUMYA for adults with active psoriatic arthritis, with a regulatory action date expected by October 29, 2026, following prior approvals for multiple psoriasis indications and broad global authorizations (Product related announcement).Narratiefupdate • Mar 28
SUNPHARMA: Obesity And Diabetes Launches And Disciplined Mergers Will Guide Balanced Outlook
Analysts have trimmed their price target for Sun Pharmaceutical Industries slightly to around ₹1,961 from about ₹1,976, reflecting updated assumptions that keep revenue growth, profit margin and future P/E expectations broadly similar to prior estimates. What's in the News Launch of semaglutide injections Noveltreat and Sematrinity in India for chronic weight management and type 2 diabetes, with weekly therapy costs reported in the INR 750 to INR 2,000 range to support affordability across multiple dose strengths (Key Developments).Narratiefupdate • Mar 12
SUNPHARMA: Obesity And Diabetes Pipeline And Mergers Will Shape Balanced Outlook
Analysts have nudged their implied fair value for Sun Pharmaceutical Industries slightly higher from ₹1,967.71 to ₹1,976.35, reflecting small adjustments to revenue growth, profit margin assumptions and the future P/E multiple in their models. What's in the News Sun Pharma received approval from the Drugs Controller General of India to manufacture and market a generic semaglutide injection for chronic weight management in adults, to be launched as Noveltreat after patent expiry in India, with multiple dose strengths offered via a prefilled pen (Key Developments).Narratiefupdate • Feb 25
SUNPHARMA: Obesity And Diabetes Franchise Will Support Long Term Upside
Analysts have made a minor upward adjustment to their fair value estimate for Sun Pharmaceutical Industries to ₹1,967.71 from ₹1,963.26, reflecting slightly higher assumptions for revenue, profit margins and future P/E. What's in the News Sun Pharma is evaluating acquisitions that it believes could strengthen its long term capabilities, with management indicating it is open to using debt financing if the target, cash flow profile and repayment visibility are acceptable, while emphasizing that media reports about specific targets are speculative and that any deals would follow a disciplined approach to mergers and acquisitions.Narratiefupdate • Feb 11
SUNPHARMA: Obesity And Diabetes Pipeline Will Drive Long Term Upside
Analysts have trimmed their price target on Sun Pharmaceutical Industries by around ₹2. This reflects updated assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E that remain broadly consistent with their earlier view.Analyseartikel • Feb 05
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹11.00
Sun Pharmaceutical Industries Limited ( NSE:SUNPHARMA ) will increase its dividend on the 16th of February to ₹11.00...Analyseartikel • Feb 03
Results: Sun Pharmaceutical Industries Limited Beat Earnings Expectations And Analysts Now Have New Forecasts
Sun Pharmaceutical Industries Limited ( NSE:SUNPHARMA ) just released its third-quarter report and things are looking...Analyseartikel • Jan 30
Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Share Price Not Quite Adding Up
When close to half the companies in India have price-to-earnings ratios (or "P/E's") below 23x, you may consider Sun...Narratiefupdate • Jan 28
SUNPHARMA: Obesity Treatments And Organon Bid Will Drive Long Term Upside
Analysts have nudged their price target for Sun Pharmaceutical Industries slightly higher to ₹1,965.29 from ₹1,955.16, reflecting small adjustments in projected revenue growth and future P/E assumptions, while the discount rate and profit margin outlook remain broadly unchanged. What's in the News Sun Pharmaceutical Industries received approval from the Drugs Controller General of India to manufacture and market a generic semaglutide injection for chronic weight management.Narratiefupdate • Jan 12
SUNPHARMA: Obesity And Psoriasis Pipeline Will Drive Long Term Upside
Analysts have nudged their fair value estimate for Sun Pharmaceutical Industries slightly higher to ₹1,955.16 from ₹1,950.68, reflecting updated assumptions around revenue growth, profit margins and the future P/E multiple. What's in the News Sun Pharma launched ILUMYA (tildrakizumab) in India for adults with moderate to severe plaque psoriasis, supported by an Indian clinical study where up to 93.9% of patients reached 75% skin clearance by week 28 and up to 78.1% reached 90% skin clearance, with the treatment reported as well tolerated.Narratiefupdate • Dec 25
SUNPHARMA: ESG Power Shift And Obesity Pipeline Will Drive Bullish Long Term Outlook
Analysts have reiterated their price target on Sun Pharmaceutical Industries at ₹1,950.68 per share, citing broadly unchanged assumptions around discount rates, long term revenue growth, profit margins, and future valuation multiples. What's in the News The U.S. FDA has approved an updated label for Sun Pharma's immunotherapy UNLOXCYT for advanced cutaneous squamous cell carcinoma, incorporating long term pivotal trial data that showed durable responses and no treatment related deaths, with commercial launch targeted for early 2026 (Key Developments).Narratiefupdate • Dec 11
SUNPHARMA: New Therapies And ESG Initiatives Will Shape Balanced Long Term Outlook
Analysts have nudged their price target for Sun Pharmaceutical Industries slightly higher to ₹1,950.68, reflecting modestly stronger long term revenue growth expectations, while largely unchanged assumptions for margins, discount rate, and future valuation multiples. What's in the News FDA approves an updated label for Sun Pharma's immunotherapy UNLOXCYT for advanced cutaneous squamous cell carcinoma, incorporating long term pivotal trial data showing durable responses and supporting a planned US commercial launch in early 2026 (FDA filing) UNLOXCYT trial results highlight rapid and sustained responses with a favorable safety profile, reinforcing Sun Pharma's strategy to expand its differentiated cutaneous oncology portfolio and pursue guideline inclusion in future NCCN updates (Company announcement) Sun Pharma reports positive Phase 1b/2a data for GL0034, a novel long acting GLP 1 receptor agonist, showing significant weight loss, liver fat reduction, and metabolic improvements in post menopausal women with obesity and metabolic liver disease, with tolerable side effects (AHA 2025 presentation) AstraZeneca Pharma India and Sun Pharma enter an exclusive second brand partnership for hyperkalemia drug Sodium Zirconium Cyclosilicate in India, with AstraZeneca marketing it as Lokelma and Sun as Gimliand to expand access across the country (Company announcement) Board approves a proposal to amend Sun Pharma's Memorandum of Association to enable setting up captive solar, renewable, and other power plants, including sale of surplus power to the grid, in line with long term ESG and sustainability goals, subject to shareholder and regulatory approvals (Board resolution) Valuation Changes Fair Value: Unchanged at approximately ₹1,950.68 per share, reflecting stable overall valuation assumptions.Narratiefupdate • Nov 27
SUNPHARMA: Revenue Projections And New Approvals To Shape Outlook In 2024
Analysts have raised their price target for Sun Pharmaceutical Industries from ₹1,930 to ₹1,951, citing improved revenue growth projections as well as slight adjustments to profitability and valuation metrics. What's in the News The U.S. FDA approved an updated label for Sun Pharma's UNLOXCYT (cosibelimab-ipdl) for metastatic and locally advanced cutaneous squamous cell carcinoma (CSCC).Analyseartikel • Nov 07
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Could Easily Take On More Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analyseartikel • Oct 13
Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now
With a price-to-earnings (or "P/E") ratio of 38.7x Sun Pharmaceutical Industries Limited ( NSE:SUNPHARMA ) may be...Narratiefupdate • Sep 04
Specialty Therapies And Emerging Markets Will Unlock Future Potential
With both the Future P/E (41.57x) and Net Profit Margin (22.70%) remaining essentially unchanged, analysts have left their consensus price target for Sun Pharmaceutical Industries steady at ₹1930. What's in the News Sun Pharma announced positive top-line results from two Phase 3 studies (INSPIRE-1 & INSPIRE-2) of ILUMYA (tildrakizumab) for active psoriatic arthritis, meeting primary endpoints with no new safety signals.Analyseartikel • Aug 04
Earnings Miss: Sun Pharmaceutical Industries Limited Missed EPS By 22% And Analysts Are Revising Their Forecasts
Shareholders might have noticed that Sun Pharmaceutical Industries Limited ( NSE:SUNPHARMA ) filed its first-quarter...Analyseartikel • Jun 27
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Will Pay A Dividend Of ₹5.50
The board of Sun Pharmaceutical Industries Limited ( NSE:SUNPHARMA ) has announced that it will pay a dividend of ₹5.50...Analyseartikel • Jun 26
What Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Not Telling You
With a price-to-earnings (or "P/E") ratio of 36.7x Sun Pharmaceutical Industries Limited ( NSE:SUNPHARMA ) may be...
Nieuw narratief • Nov 07
Robust Product Pipeline And Market Expansion Drive Growth Amidst Challenges
U.S. and India sales, driven by market leadership and product launches, enhance revenue growth and net margins via economies of scale.CEO
Kirti Ganorkar (59 yo)
less than a year
Tenure
Mr. Kirti Wardhaman Ganorkar was Non-Employee Independent Director of Krystal Biotech, Inc. from September 2017 to December 31, 2025. He serves as a Head of India Business of Sun Pharmaceutical Industries...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman of the Board | 33.3yrs | ₹64.80m | 9.6% ₹ 412.1b | |
| COO, Head of Global Generics R&D | 1.3yrs | ₹75.80m | 0.12% ₹ 5.1b | |
| Managing Director | less than a year | geen gegevens | 0.00042% ₹ 18.0m | |
| Executive VP & CFO | less than a year | geen gegevens | geen gegevens | |
| EVP & Chief Information Officer | 2.2yrs | geen gegevens | geen gegevens | |
| VP, Head of Investor Relations & Strategic Projects | no data | geen gegevens | geen gegevens | |
| Company Secretary & Compliance Officer | 4.4yrs | geen gegevens | geen gegevens | |
| Director of Corporate Development | no data | ₹65.30m | geen gegevens | |
| Head of Marketing | less than a year | geen gegevens | geen gegevens | |
| Chief Human Resources Officer | 2.5yrs | geen gegevens | geen gegevens | |
| Head of Corporate Relations & CSR - India Regulatory Affairs | no data | geen gegevens | geen gegevens | |
| Executive Vice-President of Global Operations | no data | geen gegevens | geen gegevens |
1.1yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van SUNPHARMA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.1 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman of the Board | 33.3yrs | ₹64.80m | 9.6% ₹ 412.1b | |
| COO, Head of Global Generics R&D | 3yrs | ₹75.80m | 0.12% ₹ 5.1b | |
| Managing Director | no data | geen gegevens | 0.00042% ₹ 18.0m | |
| Whole-time Director | 1.4yrs | geen gegevens | 0.12% ₹ 5.0b | |
| Non-Executive Independent Director | 8.1yrs | ₹9.80m | 0.00033% ₹ 14.2m | |
| Independent Director | 3yrs | ₹6.60m | geen gegevens | |
| Lead Independent Director | 5.1yrs | ₹10.80m | geen gegevens | |
| Independent Director | less than a year | geen gegevens | geen gegevens |
3.0yrs
Gemiddelde duur
67yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van SUNPHARMA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/09 15:54 |
| Aandelenkoers aan het einde van de dag | 2026/06/09 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Sun Pharmaceutical Industries Limited wordt gevolgd door 60 analisten. 34 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Parin Tanna | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |